This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Drange, M. R. Articles by Melmed, S. Search for Related Content PubMed PubMed Citation Articles by Drange, M. R. Articles by Melmed, S.

Pituitary Tumor Registry: A Novel Clinical Resource¹

Cedars-Sinai Research Institute, University of California–Los Angeles School of Medicine, Los Angeles, California 90048

Address correspondence and requests for reprints to: Shlomo Melmed, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048. E-mail: Melmed{at}cshs.org

Pituitary adenomas result in clinical sequelae and accelerated mortality due to central mass effects or pituitary hormone hypersecretion and/or insufficiency. The low annual incidence and prolonged natural history of these rare tumors has hindered efforts to evaluate long-term clinical outcomes. Care of these patients is often provided by larger tertiary specialist referral centers. A novel evidence-based computerized pituitary tumor registry was developed to systematically evaluate epidemiological, biochemical, and clinical outcome data. Retrospective registration of 371 patients [99 clinically nonfunctioning tumors (CNFTs), 176 acromegalics, and 96 prolactinomas] with radiological, biochemical, and clinical evidence of pituitary tumors was performed. Analysis of this primarily specialist-referred population revealed a female predominance among CNFT (60%) and prolactinoma (69%) patients. Males had a significantly greater frequency of macroadenomas than females for CNFTs (92% vs. (68%) and for prolactinomas (74% vs. 40%). Males with prolactinomas also had higher mean pretreatment serum PRL levels (1206 vs. 219 ng/mL). Concurrent hyperprolactinemia was present in CNFT (47%) and acromegaly (33%) patients. Radiographic cure, defined as absence of visualized tumor, was achieved in 21% of CNFTs, 34% of acromegalies, and 21% of prolactinomas. Biochemical remission, defined by normalization of hormonal tumor markers, was observed in 35% of acromegaly and 39% of prolactinoma patients in the registry, thus reflecting the tertiary referral patterns. Nine premature deaths (patients aged 65 yr) occurred in the acromegaly subpopulation, whereas no premature deaths were encountered in nonacromegalic patients.

In conclusion, this unique and comprehensive pituitary tumor registry enables identification of diagnostic and prognostic markers and evaluation of long-term clinical outcomes. Prospectively, this registry will improve therapeutic guidelines and cost-effective pituitary tumor management.

This article has been cited by other articles:

				G. F Taboada, R. M Luque, L. V. Neto, E. d. O Machado, B. C Sbaffi, R. C Domingues, J. B Marcondes, L. M C Chimelli, R. Fontes, P. Niemeyer, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR Eur. J. Endocrinol., March 1, 2008; 158(3): 295 - 303. [Abstract] [Full Text] [PDF]

				M. Bex, R. Abs, G. T'Sjoen, J. Mockel, B. Velkeniers, K. Muermans, and D. Maiter AcroBel the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects Eur. J. Endocrinol., October 1, 2007; 157(4): 399 - 409. [Abstract] [Full Text] [PDF]

				P. J. Goadsby, S. Kapoor, F. J. Haddy, and S. Melmed Acromegaly N. Engl. J. Med., March 22, 2007; 356(12): 1274 - 1276. [Full Text] [PDF]

				M. Georgitsi, A. Raitila, A. Karhu, K. Tuppurainen, M. J. Makinen, O. Vierimaa, R. Paschke, W. Saeger, R. B. van der Luijt, T. Sane, et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations PNAS, March 6, 2007; 104(10): 4101 - 4105. [Abstract] [Full Text] [PDF]

				A. Gurlek, N. Karavitaki, O. Ansorge, and J. A H Wass What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics Eur. J. Endocrinol., February 1, 2007; 156(2): 143 - 153. [Abstract] [Full Text] [PDF]

				S. Melmed Acromegaly N. Engl. J. Med., December 14, 2006; 355(24): 2558 - 2573. [Full Text] [PDF]

				E. Ferrante, M. Ferraroni, T. Castrignano, L. Menicatti, M. Anagni, G. Reimondo, P. Del Monte, D. Bernasconi, P. Loli, M. Faustini-Fustini, et al. Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors Eur. J. Endocrinol., December 1, 2006; 155(6): 823 - 829. [Abstract] [Full Text] [PDF]

				R. Yu, V. Bonert, I. Saporta, L. J. Raffel, and S. Melmed Aryl Hydrocarbon Receptor Interacting Protein Variants in Sporadic Pituitary Adenomas J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 5126 - 5129. [Abstract] [Full Text] [PDF]

				A. S. Dumont, E. C. Nemergut II, J. A. Jane Jr, and E. R. Laws Jr Postoperative Care Following Pituitary Surgery J Intensive Care Med, May 1, 2005; 20(3): 127 - 140. [Abstract] [PDF]

				A. Lacerte, E.-H. Lee, R. Reynaud, L. Canaff, C. de Guise, D. Devost, S. Ali, G. N. Hendy, and J.-J. Lebrun Activin Inhibits Pituitary Prolactin Expression and Cell Growth through Smads, Pit-1 and Menin Mol. Endocrinol., June 1, 2004; 18(6): 1558 - 1569. [Abstract] [Full Text] [PDF]

				F. G. Barker II, A. Klibanski, and B. Swearingen Transsphenoidal Surgery for Pituitary Tumors in the United States, 1996-2000: Mortality, Morbidity, and the Effects of Hospital and Surgeon Volume J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4709 - 4719. [Abstract] [Full Text] [PDF]

				M. U. Chaudhry A 60-year-old man with progressive malaise, fatigue and decreased libido Can. Med. Assoc. J., September 2, 2003; 169(5): 445 - 445. [Full Text] [PDF]

				S. J. Marx and L. K. Nieman Aggressive Pituitary Tumors in MEN1: Do They Refute the Two-Hit Model of Tumorigenesis? J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 453 - 456. [Full Text] [PDF]

				E. J. Lee, W. R. Duan, M. Jakacka, B. D. Gehm, and J. L. Jameson Dominant Negative ER Induces Apoptosis in GH4 Pituitary Lactotrope Cells and Inhibits Tumor Growth in Nude Mice Endocrinology, September 1, 2001; 142(9): 3756 - 3763. [Abstract] [Full Text] [PDF]